Patent Baristas
Besides patent law and litigation issues, Patent Baristas covers items relating to building a bioscience business, nanotechnology, technology transfer, orange book filings as well as FTC and FDA regulatory matters.
Author: Editor-in-chief barista Stephen Albainy-Jenei is the founder and owner of Patent Baristas. He is also a partner at Frost Brown Todd in Cincinnati. When not serving up patent chat over a cup of java, he's handling a diverse intellectual property practice in the biotechnology, pharmaceutical and chemical fields for leading research institutes, as well as biotechnology and pharmaceutical companies ranging from start-up to Fortune 500 companies.
Blawg Related Categories: Government Law • Intellectual Property Law • Patent Law • Science & Technology Law • Trials & Litigation • Partner • Blawg 100
Recent Posts from Patent Baristas
-
Teva Reveals “Man on the Street” Wants Lower Healthcare Costs. Surprised?
Teva Pharmaceuticals USA, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., is making a full-court press on getting the word out on the need for follow-on biologics. In its “Year of Affordable Healthcare” campaign, Teva…
-
Maximizing Pharmaceutical Patent Lifecycles
The American Conference Institute’s Maximizing Pharmaceutical Patent Lifecycles, the 10th Anniversary Edition will be held at the Helmsley Park Lane Hotel, New York, New York, on Wednesday, October 7, 2009 to Thursday, October 8, 2009.…
-
Monday Book Review: This Time It’s Your Book
Last week’s book review was on the Annual Review of Intellectual Property Law Developments: 2006-2008, by the American Bar Association (ABA) Section of Intellectual Property Law. This week, we’re giving you a chance to get…
-
Administration’s First Volley on Biosimilars: 7 Years of Exclusivity is Long Enough
The Obama Administration sent out a warning shot that seven years is enough time to protect brand-name biotechnology medicines from generic competitors. In a letter to Representative Henry Waxman (D-CA), the White House set out…
-
Senate Bill Would Allow Generics to Share 180 Day Exclusivity
Sens. Bill Nelson [D, FL] and Sen. Herbert Kohl [D, WI] have introduced a bill (s. 1315) to amend the Federal Food, Drug, and Cosmetic (Hatch-Waxman) Act to define the term “first applicant” for purposes…